A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Santa Barbara, California 93105, United States
805-682-7638
Philadelphia, Pennsylvania 19104, United States
Marseille, 13385, France
Paris, 75019, France
Dresden, 01307, Germany
Beer Yaacov, 70300, Israel
97289542166
Verona, 37126, Italy
Lørenskog, 1478, Norway
Vila Nova de Gaia, 4434-502, Portugal
850-431-5404
319-356-4511
515-329-6800
502-629-5820
267-426-7037
+61736468111
02 9845 3171
0475956681
3227647052
0032 8214364
+3216346994
+32-81-720505
554130231252
5562992240229
55 14 21051477
551127370277
551126303777
551197116-9844
604-683-3734 x 1001
358503539956
33472129525
33161693086
33 491388384
01 44 49 48 01
33140032000
33 5 61 32 30 18
00498212412200
00498214009201
03514587510
004951181153331
0049 89 3187 2896
97286244150
97247774411
972-9-9613210
97226776927
972-97472559
97239253282
+97239377183
+972035302021
035308469
+9728-9441361
97236974863
390715962011
0512143009
+39 070 52965605
3384034476
0226432818
+390817462311
3903213733350
3357940960
0458127662
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
+31-88-280-7277
+4797522277
+48502056191
+351914125573
961790293
946006000
+34621360800
+44 1223 336994
02920742274
07885278793
01865231729
02381208518